Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2010-4-8
pubmed:abstractText
Transplant-related problems have been partially overcome by using reduced-intensity conditioning (RIC), graft engineering, and alternative donors. In all, 21 leukemia patients with no suitable donor received a hematopoietic stem cell transplantation from a mismatched/haploidentical related (n=16) or unrelated donor (n=5). Fludarabine-RIC and PBSC graft were used. Manipulation was done by CD34+ selection (n=9) or CD3/CD19 depletion (n=12). Results were compared with patients (n=26) conditioned with the same regimen and grafted with a CD34+-selected PBSC from identical related donors. Median time to neutrophil recovery was 12 days (range, 10-19 d). Platelet engraftment was faster with a CD3/CD19-depleted graft (median, 11 d; range, 9-21) than with a CD34+ graft (median, 14 d; range, 9-53; P=0.003). Full donor chimerism in bone marrow CD34+ cells was higher in CD3/CD19-depleted graft group compared with CD34+-selected group (P=0.02). CD3/CD19 depletion showed higher natural killer cell counts even after 1 year. Nonrelapse mortality (7% for matched CD34+-selected grafts and 11% for mismatched/haplo-CD3/CD19-depleted grafts), relapse probability (27% for related CD34+-selected patients and 33% for related CD3/CD19-depleted patients), and disease-free survival were similar for both the groups. In conclusion, using graft engineering procedures after RIC for hematopoietic stem cell transplantation offers a high probability of engraftment, fast immune recovery, and very low mortality even with mismatched donors.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1536-3678
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
32
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
e85-90
pubmed:dateRevised
2011-10-6
pubmed:meshHeading
pubmed-meshheading:20216238-Adolescent, pubmed-meshheading:20216238-Antigens, CD19, pubmed-meshheading:20216238-Antigens, CD3, pubmed-meshheading:20216238-Antineoplastic Agents, pubmed-meshheading:20216238-Child, pubmed-meshheading:20216238-Child, Preschool, pubmed-meshheading:20216238-Disease-Free Survival, pubmed-meshheading:20216238-Female, pubmed-meshheading:20216238-Graft Rejection, pubmed-meshheading:20216238-Graft Survival, pubmed-meshheading:20216238-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:20216238-Histocompatibility Testing, pubmed-meshheading:20216238-Humans, pubmed-meshheading:20216238-Infant, pubmed-meshheading:20216238-Leukemia, Myeloid, Acute, pubmed-meshheading:20216238-Lymphocyte Count, pubmed-meshheading:20216238-Male, pubmed-meshheading:20216238-Myeloablative Agonists, pubmed-meshheading:20216238-Precursor Cell Lymphoblastic Leukemia-Lymphoma, pubmed-meshheading:20216238-Prospective Studies, pubmed-meshheading:20216238-Tissue Donors, pubmed-meshheading:20216238-Transplantation, Homologous, pubmed-meshheading:20216238-Transplantation Conditioning, pubmed-meshheading:20216238-Treatment Outcome, pubmed-meshheading:20216238-Vidarabine
pubmed:year
2010
pubmed:articleTitle
Graft manipulation and reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation from mismatched unrelated and mismatched/haploidentical related donors in pediatric leukemia patients.
pubmed:affiliation
Department of Pediatrics, Division of Pediatric Hematology-Oncology and Hematopoietic Stem Cell Transplantation and Cell Therapy Unit, Niño Jesus Children Hospital, Madrid, Spain.
pubmed:publicationType
Journal Article